When combined with anti-PD1 therapy, this strategy significantly delayed tumor progression in 4T1 and B16 melanoma tumor models with a substantial increase in infiltrated antitumor CD8+/CD4+ T cells and NK cells and a reduced population of T-regs in the TME. The gene discussed is CD8A; the disease is neoplasm.